Renal Cell Carcinoma is More Aggressive in Turkish Patients with the Metabolic Syndrome

  • Ozbek, Emin (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Otunctemur, Alper (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Sahin, Suleyman (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Dursun, Murat (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Besiroglu, Huseyin (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Koklu, Ismail (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Polat, Emre Can (Department of Urology, Balikligol State Hospital) ;
  • Erkoc, Mustafa (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Danis, Eyyup (Department of Urology, Okmeydani Training and Research Hospital) ;
  • Bozkurt, Muammer (Department of Urology, Okmeydani Training and Research Hospital)
  • Published : 2013.12.31


Background: Metabolic syndrome (MetS) is a multifactorial disease characterized by impaired glucose tolerance/diabetes, obesity, high triglyceride levels, low HDL levels, and hypertension. In this study we evaluate the relationship between tumor size and grade, and presence of the metabolic syndrome in patients with renal cell carcinoma. Materials and Methods: Between 2007-2013, radical nephrectomy was performed for 310 patients with renal tumors in our clinic and those with pathology reported renal cell carcinoma were enrolled and divided into two groups, with and without metabolic syndrome diagnosed on the basis of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria. The relationship between tumor size and grade of the two groups (Fuhrman nuclear degree) was evaluated statistically. Results: The metabolic syndrome was found in 70 patients, with a mean age of 65.5 (40-87), as compared to 58.8 (31-84) years in the non-metabolic syndrome group. Tumor size over 7 cm was found in 54% and 33%, respectively, and tumor grade over Fuhrman 3 in 56% and 32% of patients. Patients with metabolic syndrome had significantly higher tumor size and grade (p<0.05). In the presence of hypertension, diabetes and high triglyceride levels, significant assocations were again observed (p<0.05). Tumor size and degree also increased with increasing body mass index but this was not statistically significant (p>0.05). Conclusions: Renal cancer is more aggressive in patients with metabolic syndrome. Lifestyle and risk factors were revealed to be significant influences in renal cancer patients.


  1. Bruce WR, Giacca A, Medline A (2000). Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev, 9, 1271-9.
  2. Bergstrom A, Hsieh CC, Lindblad P, et al (2001). Obesity and renal cell cancer a quantitative review. Br J Cancer, 85, 984.
  3. Bowers K, Albanes D, Limburg P, et al (2006). A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol, 164, 652-64.
  4. Chow W, Devesa S, Warren J, Fraumeni J Jr (1999). Rising incidence of renal cell cancer in the United States. JAMA, 281, 1628-31.
  5. Chow W, Gridley G, Fraumeni J, Jarvholm B (2000). Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med, 343, 1305-11.
  6. Chow WH, Dong LM, Devesa SS (2010). Epidemiology and risk factors for kidney cancer. Nat Rev Urol, 7, 245-57.
  7. Choi JB, Yoon BI, Kim SJ, et al (2011). Changes in clinicopathological characteristics of renal cell carcinoma in the past 25 years: a single-center experience. Korean J Urol, 52, 110-4.
  8. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F (2000). Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr, 71, 569-74.
  9. Eckel RH (2007). Treating dyslipidemia of the metabolic syndrome: where's the evidence? Nat Clin Pract Endocrinol Metab, 3, 437.
  10. Fiorenza AM, Branchi A, Sommariva D (2000). Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res, 30, 141-5.
  11. Flaherty KT, Fuchs CS, Colditz GA, et al (2005). A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control, 16, 1099-106.
  12. Giovannucci E (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 131, 3109-20.
  13. Gorbachinsky I, Akpinar H, Assimos DG (2010). Metabolic syndrome and urologic diseases. Rev Urol, 12, 157-80.
  14. Huang PL (2009). A comprehensive definition for metabolic syndrome. Dis Model Mech, 2, 231-7.
  15. Habib SL, Prihoda TJ, Luna M, Werner SA (2012). Diabetes and risk of renal cell carcinoma. J Cancer, 3, 42-8.
  16. Ibrahim MM (2010). Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev, 11, 11.
  17. Joh HK, Willett WC, Cho E (2011). Type 2 diabetes and the risk of renal cell cancer in women. Diabetes care, 34, 1552-6.
  18. Lindblad P, Chow WH, Chan J, et al (1999). The role of diabetes mellitus in the etiology of renal cell cancer. Diabetologia, 42, 107-12.
  19. Lowrance WT, Thompson RH, Yee DS, et al (2009). Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU International, 105, 16-20.
  20. McLaughlin JK, Chow WH, Mandel JS, et al (1995). International renal-cell cancer study VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer, 63, 216-21.
  21. Pantuck AJ, Zisman A, Belldegrun AS (2001). The changing natural history of renal cell carcinoma. J Urol, 166, 1611-23.
  22. Patard JJ, Tazi H, Bensalah K, et al (2004). The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol, 45, 490-3.
  23. Parker AS, Lohse CM, Cheville JC, et al (2006). Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urol, 68, 741.
  24. Pflug BR, Hong Z, Udan MS, et al (2007). Endothelin-1 promotes cell-survival in renal cell carcinoma through the ET[A] receptor. Cancer, 246, 139-48.
  25. Rodriguez C, Patel AV, Mondul AM, et al (2005). Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol, 161, 147-52.
  26. Rini BI, Campbell SC, Escudier B (2009). Renal cell carcinoma. The Lancet, 373, 1119-32.
  27. Shanks JH (1999). Pathology of renal cell carcinoma: recent developments. Clin Oncol (R Coll Radiol), 11, 263-8.
  28. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D (2002). A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control, 13, 417-26.
  29. Tall AR (1998). An overview of reverse cholesterol transport. Eur Heart J, 31-5.
  30. Takahashi K, Totsune K, Murakami O (2001). Expression of three vasoactive peptides, urotensin- II, adrenomedullin, and endothelin-1, in a human renal cell carcinoma cell line, VMRC-RCW. Clin Exp Nephrol, 5, 246-9.
  31. Ulmer H, Borena W, Rapp K, et al (2009). Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer, 101, 1202-6.
  32. Weikert S, Ljungberg B (2010). Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol, 28, 247-52.

Cited by

  1. Risk of Cancer Mortality according to the Metabolic Health Status and Degree of Obesity vol.15, pp.22, 2014,
  2. The Metabolic Syndrome is Associated with More Aggressive Prostate Cancer vol.15, pp.9, 2014,
  3. Kidney Cancer in Lebanon: a Specific Histological Distribution? vol.16, pp.1, 2015,
  4. Renal Cell Carcinoma and Visceral Adipose Index: a new risk parameter vol.42, pp.5, 2016,
  5. Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma vol.8, pp.2, 2017,
  6. Prevention of kidney cancer incidence and recurrence pp.0963-0643, 2017,